EAM
ADVM

Eventide Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Eventide Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-72,000
Closed -$8.56M – 125
2019
Q2 		$8.56M Sell
72,000
-42,658
-37% -$3.53M 0.26% 80
2019
Q1 		$6.01M Hold
114,658
– – 0.21% 87
2018
Q4 		$3.61M Buy
+114,658
New +$4.66M 0.16% 94
2015
Q2 		– Sell
-3,740
Closed -$1.51M – 111
2015
Q1 		$1.51M Buy
3,740
+500
+15% +$211K 0.11% 101
2014
Q4 		$1.75M Buy
3,240
+1,240
+62% +$478K 0.19% 81
2014
Q3 		$684K Buy
+2,000
New +$595K 0.1% 97

Other funds holding ADVM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Eventide Asset Management's ADVM Position: Q3 2019 in Review

Eventide Asset Management sold out of Adverum Biotechnologies (ADVM) in Q3 2019, closing a stake of 72,000 shares — an estimated $8.56M sold.

Eventide Asset Management first reported a position in ADVM in Q3 2014 and held it in 6 quarters. The position peaked at $8.56M in Q2 2019. 99 funds tracked by Wall St. Rank hold ADVM as of Q3 2019.

  • Eventide Asset Management reported no remaining Adverum Biotechnologies position as of Q3 2019 after selling out during the quarter.
  • Eventide Asset Management sold 72,000 Adverum Biotechnologies shares in Q3 2019, an estimated $8.56M.
  • Eventide Asset Management first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 6 quarters.
  • Eventide Asset Management's Adverum Biotechnologies position peaked at $8.56M in Q2 2019.
  • 99 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2019.

Based on Eventide Asset Management's 13F filing for Q3 2019, filed 21 Nov 2019.